Nuravax, Institute for Molecular Medicine to Present Phase 1 Results and Phase 2 Design of Alzheimer’s Vaccine AV-1959R at CTAD 2025
Two oral presentations to highlight the safety, immunogenicity, and future development of AV-1959R for primary and secondary prevention of Alzheimer's disease Nuravax Inc., a clinical-stage biopharmaceutical company developing active immunotherapies for neurodegenerative diseases, announced today that two oral presentations-the Phase 1 clinical results and the Phase 2 secondary prevention study design for its licensed lead […]